临床肺科杂志
臨床肺科雜誌
림상폐과잡지
JOUNAL OF CLINICAL PULMONARY MEDICINE
2015年
3期
398-401
,共4页
陈旭兰%付靖楠%张苗%张志群%屈波
陳旭蘭%付靖楠%張苗%張誌群%屈波
진욱란%부정남%장묘%장지군%굴파
非小细胞肺癌%超声与CT引导%导管消融术%靶向治疗%生命质量
非小細胞肺癌%超聲與CT引導%導管消融術%靶嚮治療%生命質量
비소세포폐암%초성여CT인도%도관소융술%파향치료%생명질량
non-small cell lung cancer%CT and ultrasound guided%catheter ablation%targeted therapy%quality of life
目的:研究超声与CT引导下导管射频消融( radiofrequency ablation,RFA)对靶向联合化学药物治疗周围型中晚期非小细胞肺癌患者生命质量的影响。方法选取90例诊断为周围型中晚期非小细胞癌的患者随机分为治疗组与对照组,每组均为45例。两组患者均给予吉非替尼联合顺铂与紫杉醇靶向治疗,治疗组在靶向化学联合治疗的基础上,行在超声与CT引导下经皮射频消融术,治疗前及治疗后4周评价两组患者的生命质量并记录不良反应。结果治疗后两组的整体功能、特异性症状各个指标及整体生命质量评分均明显优于治疗前,且治疗后治疗组上述治疗指标均优于对照组(P<0.05),治疗组治疗后出现咳嗽、胸痛、发热、咯血、气胸,两组患者治疗后均出现恶心、伴呕吐、骨髓抑制,且无统计学差异( P>0.05)。结论射频消融术联合靶向与化学治疗能改善转移灶较少的周围型中晚期非小细胞肺癌患者的生命质量。
目的:研究超聲與CT引導下導管射頻消融( radiofrequency ablation,RFA)對靶嚮聯閤化學藥物治療週圍型中晚期非小細胞肺癌患者生命質量的影響。方法選取90例診斷為週圍型中晚期非小細胞癌的患者隨機分為治療組與對照組,每組均為45例。兩組患者均給予吉非替尼聯閤順鉑與紫杉醇靶嚮治療,治療組在靶嚮化學聯閤治療的基礎上,行在超聲與CT引導下經皮射頻消融術,治療前及治療後4週評價兩組患者的生命質量併記錄不良反應。結果治療後兩組的整體功能、特異性癥狀各箇指標及整體生命質量評分均明顯優于治療前,且治療後治療組上述治療指標均優于對照組(P<0.05),治療組治療後齣現咳嗽、胸痛、髮熱、咯血、氣胸,兩組患者治療後均齣現噁心、伴嘔吐、骨髓抑製,且無統計學差異( P>0.05)。結論射頻消融術聯閤靶嚮與化學治療能改善轉移竈較少的週圍型中晚期非小細胞肺癌患者的生命質量。
목적:연구초성여CT인도하도관사빈소융( radiofrequency ablation,RFA)대파향연합화학약물치료주위형중만기비소세포폐암환자생명질량적영향。방법선취90례진단위주위형중만기비소세포암적환자수궤분위치료조여대조조,매조균위45례。량조환자균급여길비체니연합순박여자삼순파향치료,치료조재파향화학연합치료적기출상,행재초성여CT인도하경피사빈소융술,치료전급치료후4주평개량조환자적생명질량병기록불량반응。결과치료후량조적정체공능、특이성증상각개지표급정체생명질량평분균명현우우치료전,차치료후치료조상술치료지표균우우대조조(P<0.05),치료조치료후출현해수、흉통、발열、각혈、기흉,량조환자치료후균출현악심、반구토、골수억제,차무통계학차이( P>0.05)。결론사빈소융술연합파향여화학치료능개선전이조교소적주위형중만기비소세포폐암환자적생명질량。
Objective To study the effect of radiofrequency ablation combined with targeted therapy under CT and ultrasound on quality of life in the treatment of patients with non-small cell lung cancer. Methods 90 NSCLC patients at stageⅢandⅣwere randomly divided into the treatment group and the control group. All of them were treated with paclitaxel, cisplatin and gefitinib, and the treatment group was added with CT or ultrasound guided percutaneous radiofrequency ablation. Their quality of life before and 4 weeks after the treatment were compared and the adverse reactions were recorded. Results After the treatment, the allomeric function and the scores of symptom specific modules turned better (P<0. 05), and the improvement was more pronounced in the treatment group than in the control group (P<0. 05). There was no significant difference in cough, chest pain, febrile, hemoptysis, pneu-mothorax nausea, vomit and myelosuppression between the two groups. Conclusion Radiofrequency ablation guided by ultrasound and CT combined with targeted therapy and chemotherapy can improve quality of life of patients with peripheral non-small cell lung cancer at stage Ⅲ and Ⅳ.